Yanachkova Vesselina, Kamenov Zdravko
Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynaecology "Dr Shterev", Sofia, Bulgaria.
Department of Internal Medicine, Medical University - Sofia, Sofia, Bulgaria, Bulgaria.
Endokrynol Pol. 2021;72(3):226-231. doi: 10.5603/EP.a2021.0016. Epub 2021 Feb 23.
Thyroid dysfunction and gestational diabetes (GDM) are the two most common endocrine disorders that can be observed during pregnancy. Thyroid function abnormalities can be associated with insulin resistance (IR) and changes in carbohydrate metabolism. In patients with type 1 diabetes, thyroid function is usually evaluated to rule out abnormalities within a second autoimmune disease. Patients with type 2 diabetes are tested for thyroid function in view of the associated weight gain, IR, and changes in metabolism. The question arises: Should we also look for thyroid dysfunction in patients with gestational diabetes? The aim of the study was to determine whether there are abnormalities in thyroid hormone levels in pregnant women with gestational diabetes.
A monocentric, retrospective study of the Dr Shterev Hospital electronic database was performed. We analysed the medical records of 662 pregnant women, divided in two groups - 412 with GDM and 250 with normal glucose tolerance, who gave birth in the period 2017-2019. Gestational diabetes mellitus in the study group was diagnosed with a 2-h, 75-g oral glucose tolerance test (OGTT) using the International Federation of Gynaecology and Obstetrics (FIGO) and American Diabetes Association (ADA) criteria. We analysed the mean serum concentrations of thyroid-stimulating hormone (TSH); free thyroxine (FT4), free triiodothyronine (FT3), FT3:FT4 ratio, fasting plasma glucose, age and body mass index in both groups. The groups were compared using the Mann-Whitney U-test.
In patients who developed GDM, significantly higher concentrations of TSH (p < 0.0001) and FT3 (p < 0.0001), lower concentrations of FT4 (p < 0.0001), and higher FT3:FT4 ratios (p < 0.0001) were found.
The results of this pilot retrospective series reveal that high-normal to high concentration of TSH and low-normal to low concentration of FT4 as well as high FT3:Ft4 ratio could indicate increased risk of development of GDM.
甲状腺功能障碍和妊娠期糖尿病(GDM)是孕期最常见的两种内分泌疾病。甲状腺功能异常可能与胰岛素抵抗(IR)及碳水化合物代谢变化有关。在1型糖尿病患者中,通常会评估甲状腺功能以排除第二种自身免疫性疾病中的异常情况。鉴于2型糖尿病患者存在体重增加、IR及代谢变化,也会对其进行甲状腺功能检测。问题来了:对于妊娠期糖尿病患者,我们是否也应该检查甲状腺功能障碍?本研究的目的是确定妊娠期糖尿病孕妇的甲状腺激素水平是否存在异常。
对什捷列夫医院的电子数据库进行了一项单中心回顾性研究。我们分析了662名在2017 - 2019年期间分娩的孕妇的病历,将她们分为两组——412名患有GDM的孕妇和250名糖耐量正常的孕妇。研究组的妊娠期糖尿病通过采用国际妇产科联合会(FIGO)和美国糖尿病协会(ADA)标准的2小时75克口服葡萄糖耐量试验(OGTT)进行诊断。我们分析了两组中促甲状腺激素(TSH)、游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)、FT3:FT4比值、空腹血糖、年龄和体重指数的平均血清浓度。使用曼 - 惠特尼U检验对两组进行比较。
在发生GDM的患者中,发现TSH(p < 0.0001)和FT3(p < 0.0001)浓度显著升高,FT4(p < 0.0001)浓度降低,FT3:FT4比值升高(p < 0.0001)。
这个初步回顾性系列研究的结果表明,TSH处于高正常至高浓度、FT4处于低正常至低浓度以及FT3:Ft4比值升高可能表明发生GDM的风险增加。